Advertisement
New Zealand markets closed
  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     
  • NZD/USD

    0.5940
    +0.0006 (+0.10%)
     
  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     
  • OIL

    83.51
    +0.15 (+0.18%)
     
  • GOLD

    2,340.50
    -1.60 (-0.07%)
     

How Is Teva Progressing with Its Specialty Assets Portfolio?

How Is Teva Progressing with Its Specialty Assets Portfolio?

Teva Pharmaceutical (TEVA) is focused on advancing its specialty assets portfolio, one of its key growth drivers. The company’s specialty products portfolio is made up of Copaxone, Austedo, Fremanezumab, and a number of other assets that are in clinical trials, one of which is Fasinumab.